The Board of Directors of the Company have approved the Standalone Unaudited Financial Results for the quarter ended on 30th June 2025 of the financial year 2025-26.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
BDH Industries reported standalone unaudited results for Q1 FY26 (quarter ended 30 June 2025). Revenue from operations rose to ₹1,862.42 lakhs, up about 14.6% from ₹1,625.82 lakhs in the same quarter last year. Total income stood at ₹1,916.98 lakhs versus ₹1,663.44 lakhs year-on-year. Profit after tax grew to ₹182.66 lakhs from ₹156.85 lakhs, a rise of roughly 16.5%, with EPS of ₹3.17 compared to ₹2.17 earlier. The Pharmaceuticals segment remains the dominant business (₹1,830.22 lakhs revenue), while Renewable Energy contributed a small ₹32.20 lakhs. Finance costs were negligible at ₹0.53 lakhs, and the statutory auditor CLB & Associates issued an unmodified limited review report with no qualifications or concerns raised.
A steady quarter with double-digit revenue and profit growth, low debt, and a clean audit report — broadly positive for shareholders, though growth rates are modest and below the standout 20%+ thresholds that often move small-cap pharma stocks.